Potential Breakthrough Investment Opportunity!
NASDAQ:LIXT
Despite major advances in oncology, a significant gap remains between existing cancer treatments and the outcomes patients need. Many tumors develop resistance to chemotherapy, immunotherapy, and radiation, limiting long-term effectiveness. Treatment toxicity further restricts dosing and duration, reducing therapeutic impact. At the same time, access to advanced radiotherapy technologies remains limited due to high infrastructure costs and scalability barriers. These challenges leave a substantial portion of patients without effective options. The market urgently needs modalities that enhance existing treatments, overcome resistance, and increase accessibility, creating a clear opportunity for next-generation oncology platforms.
Cancer remains one of the world’s most urgent healthcare challenges. In 2022, more than 20 million people were newly diagnosed, and 9.7 million died, with global cases projected to rise to 35 million by 2050. Today, 1 in 5 individuals will develop cancer, and nearly 1 in 10 will die from it. Lung, breast, colorectal, prostate, and cervical cancers dominate incidence and mortality worldwide. Despite lower incidence in low-income countries, mortality is significantly higher due to limited screening and treatment access. Over 50% of cancer deaths are preventable, underscoring the unmet need for more effective therapies, precision radiotherapy, and treatment-amplifying technologies—areas where oncology innovation can create both clinical impact and long-term value. ii
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) addresses these critical gaps with a dual-innovation strategy built around LB-100, a first-in-class PP2A inhibitor that amplifies the effectiveness of chemotherapy, immunotherapy, and radiation by overcoming tumor resistance. Complementing this drug platform, LIXTE’s acquisition of the LiGHT Proton Therapy System introduces a next-generation radiotherapy technology designed to deliver greater precision at significantly lower infrastructure cost. Together, these modalities create a unified solution that strengthens existing treatments, expands access to advanced care, and positions LIXTE as a differentiated oncology platform capable of delivering meaningful clinical and commercial impact across high-need cancer indications.
LB-100 is Lixte Biotechnology’s (Nasdaq: LIXT) lead molecule and the first-in-class clinical-stage PP2A inhibitor designed to make existing cancer treatments work more effectively.
As a clinical-stage company developing a new class of oncology therapies, Lixte focuses on enhancing the performance of chemotherapy, immunotherapy, and radiation—modalities that already play central roles across many tumor types. While immunotherapy has transformed cancer care in recent years, its effectiveness remains limited in tumors that are resistant or immunologically “cold.”
LB-100 addresses this challenge by disabling a key cellular checkpoint that tumors use to recover from treatment stress. The result is amplified therapeutic impact: improved immune visibility, disrupted DNA repair, and strong synergy with chemotherapy and immunotherapy observed across multiple pre-clinical models—all supported by a favorable safety profile in clinical studies.
Pre-Clinical Evidence: LB-100 is a first-in-class enhancer of immunotherapy
Learn More about Lixte Biotechnology Holdings, Inc. by gaining access to the latest research report
LIXTE’s acquisition of Liora Technologies brings the revolutionary LiGHT Proton Therapy Platform into its oncology portfolio—a next-generation radiotherapy system designed to expand global access to precision cancer care. With more than $300 million invested in its development and validated 230 MeV clinical performance, LiGHT delivers highly controlled, electronically tuned proton beams with near-3D accuracy, enabling treatment that targets tumors while sparing surrounding healthy tissue.
This breakthrough matters because proton therapy is widely regarded as the most precise form of radiotherapy available today, yet traditional systems cost $200–$300 million, require massive infrastructure, and take 3–5 years to install. As a result, only 300 treatment rooms exist worldwide, leaving an estimated 9,500-room global shortfall and millions of patients without access.
LiGHT directly addresses this gap. Its compact LINAC-based architecture lowers facility cost to roughly $85 million for up to four rooms—about 30% the cost of legacy systems—while reducing complexity and shortening deployment timelines. The technology’s precision can meaningfully improve quality of life for patients, from protecting developing brains in pediatric tumors to preserving organ function in prostate and other anatomically sensitive cancers.
“The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies, We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.”
“Our plan is to bring the LiGHT system to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model through jointly operated treatment centers. The addition of Liora also represents an excellent complement to the pharmaceutical side of our business and our ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.”
The global oncology market represents one of the largest and fastest-growing arenas in healthcare. Valued at $321.9 billion in 2024, and surge to $903.8 billion by 2034, reflecting a 10.9% CAGR iv.
Within this landscape, LIXTE targets high-need, high-value segments with significant commercial potential. The colorectal cancer drug market is projected to grow from $12.6 billion in 2024 to $19.96 billion by 2033 (5.2% CAGR) vi.
The ovarian cancer drug market is expected to expand from $3.84 billion in 2024 to $7.34 billion by 2034 (6.7% CAGR) vii. Meanwhile, soft-tissue sarcoma therapies are set to rise from $1.4 billion in 2024 to $2.86 billion by 2035 viii (6.72% CAGR) .
Together, these markets underscore the substantial growth runway and value potential for LIXTE’s multi-modal oncology platform.
Learn More about Lixte Biotechnology Holdings, Inc. by gaining access to the latest research report
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) enters a defining stage in its evolution, advancing two high-impact technologies designed to reshape cancer treatment. The company’s lead molecule, LB-100, introduces a first-in-class PP2A inhibition strategy aimed at enhancing the effectiveness of chemotherapy, immunotherapy, and radiation across multiple resistant tumor types.
Alongside this therapeutic innovation, LIXTE has expanded into precision radiotherapy through the acquisition of Liora Technologies and its LiGHT Proton Therapy Platform, a next-generation system developed with scientific leadership linked to CERN and advanced engineering validated at the STFC Daresbury Laboratory. This platform positions the company to address the global shortfall in proton therapy capacity.
Collaborations with GSK, Roche, MD Anderson Cancer Center, Northwestern University, and the Netherlands Cancer Institute further strengthen the clinical and scientific foundation supporting LB-100’s development. Each partnership reinforces progress toward broader clinical adoption across high-need cancer indications.
These combined assets place LIXTE in a substantial and rapidly expanding oncology market, creating a differentiated opportunity for investors evaluating emerging multi-modal cancer platforms.
First-in-Class PP2A Inhibitor (LB-100): LB-100 is the only clinical-stage PP2A inhibitor, a novel mechanism that sensitizes tumors to chemotherapy, immunotherapy, and radiation by disabling a key cellular recovery checkpoint.
Breakthrough LiGHT Proton Therapy Platform (Liora Technologies): The LiGHT System is a compact, electronically controlled LINAC-based proton therapy solution validated at 230 MeV, designed to deliver high-precision beams with a much smaller footprint than legacy systems.
Revolutionary LINAC Technology Is the Key Differentiator: LINAC architecture enables rapid, electronic energy tuning and near-3D dose control (up to 200 adjustments/sec), offering clinical flexibility and treatment precision that legacy cyclotron systems cannot match.
Game-Changing Economics: ~70% Cost Reduction: LiGHT targets an ~30% cost of legacy installations — roughly $85M for a four-room facility versus $200–$300M historically — dramatically lowering the financial barrier to proton therapy adoption.
Addresses a 9,500-Room Global Shortfall: With only ~300 proton therapy rooms today, the estimated 9,500-room gap creates substantial unmet demand; LiGHT’s scalability directly targets this structural market opportunity.
Debt-Free Position: LIXTE carries no long-term debt, providing financial flexibility and a stronger foundation for growth. ix
World-Class Scientific Credibility: CERN Leadership & UK Government Partnership: Technical leadership linked to CERN (Professor Steve Myers) and development/testing at STFC’s Daresbury Laboratory provide institutional validation and engineering depth uncommon for a micro-cap.
Proven Business Model with Ongoing Revenue Potential: A JV/operational model (equipment + clinical operations) enables recurring revenue from treatments, maintenance, and service contracts, turning one-time device sales into long-term cash flow streams.
Robust Clinical Collaborations & Pharma Partnerships: Active, funded trials with partners such as GSK and Roche and investigator sites at MD Anderson, Northwestern, and Netherlands Cancer Institute accelerate clinical validation and de-risk development pathways.
Strong Preclinical and Early Clinical Evidence: Extensive preclinical synergy data and favorable Phase 1 tolerability support LB-100’s amplifier thesis, including peer-reviewed publications and Nature-level validation of the PP2A biology.
Growing Oncology Market Opportunity: The global oncology market was $321.9 billion in 2024 and surge to $903.8 billion by 2034 (CAGR 10.9%). Target segments include colorectal drugs (US$12.6B in 2024 → US$19.96B by 2033, 5.2% CAGR), ovarian cancer drugs (US$3.84B in 2024 → US$7.34B by 2034, 6.7% CAGR), and soft-tissue sarcoma therapies (US$1.4B in 2024 → US$2.86B by 2035, ~6.72% CAGR), underscoring significant commercial runway for both LB-100 combinations and expanded radiotherapy capacity.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors.
The Company's innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company's therapy is LB-100, the Company's proprietary compound that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile.
LB-100 promotes the production of neoantigens and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes.
The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE's unique approach has no known competitors and is covered by a comprehensive patent portfolio.
Clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors.
Our innovative approach enhances the efficacy of chemotherapies and immunotherapies, potentially providing new options for cancer patients.
Our proprietary compound LB-100 acts as a safe and potent inhibitor of PP2A.
Conducting multiple clinical trials for solid tumors, including Advanced Soft Tissue Sarcoma Ovarian Clear Cell Cancer and Small Cell Lung Cancer.
Compact, precise, and accessible proton therapy through innovative LINAC technology
Learn More about Lixte Biotechnology Holdings, Inc. by gaining access to the latest research report
Proton therapy has been around for decades, but it’s remained out of reach for most patients because of the massive infrastructure required. Traditional systems use cyclotrons or synchrotrons housed in buildings that can be 3-4 stories tall and require hundreds of tons of shielding.
LiGHT uses a modular linear accelerator (LINAC) design that’s 20-30 times smaller than legacy gantry systems. Instead of requiring massive concrete vaults and multi-ton rotating equipment, LiGHT’s components fit in smaller treatment rooms and require lighter shielding.
LiGHT (Linac for Image Guided Hadron Therapy) represents a paradigm shift in proton therapy delivery.
The system delivers electronically adjustable proton beam energy in real time – up to 200 adjustments per second. This enables precision 3D tumor targeting with the same accuracy as traditional systems but in a fraction of the space and at a fraction of the cost.
LIXTE is positioned at a rare intersection of validated technology and near-term commercial potential. The LiGHT Proton Therapy Platform has already achieved its 230 MeV milestone at STFC Daresbury with $300M+ invested, addressing a 9,500-room global shortfall in proton therapy access at a dramatically lower cost. At the same time, LB-100, the only clinical-stage PP2A inhibitor, continues to demonstrate synergy with chemotherapy, immunotherapy, and radiation in high-need cancer types.
Both platforms target major gaps in oncology and benefit from established regulatory pathways and strong institutional partnerships. With LiGHT approaching operational readiness and LB-100 advancing through funded collaborations, this combination is drawing increasing investor interest—and the opportunity may not remain overlooked for long.
An accomplished executive and entrepreneur with 10+ years of experience in M&A, capital markets, strategy, and operations.
Known for innovative leadership across tech, logistics, CX, sports, and marketing, he excels at scaling businesses, raising capital, and executing transformative strategies in public and private markets with a strong, value- driven approach.
Biotechnology Executive with more than 20 years experience in bringing innovation to the patient. Most recently the Chief Clinical Officer of Agendia
Specialized in precision oncology and business development. Extensive experience in clinical development overseeing numerous clinical trials from start to publication.
Seasoned CFO with 25 years of expertise in finance operations management and accounting across start-ups, high-growth ventures, and multi-billion-dollar enterprises. Since 2018, he has served on the Board of Directors of Beyond Commerce and as Chairman of the Audit Committee, Peter holds an MBA in Finance from DePaul University and a BS in Accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant (CPA).
• Leader in the field of molecular carcinogenesis
• Extensive experience in cancer drug development
• International member, National Academy of Sciences, US
• Distinguished cancer investigator
• Former Chairman Mol. Pharmacology City of Hope
• Former President of Taipei Medical University
• International KOL in hematological cancers
• Professor of Hematology & Hematopoietic Cell Transplantation City of Hope National Medical Center
Learn More about Lixte Biotechnology Holdings, Inc. by gaining access to the latest research report
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is advancing a multi-modal oncology strategy built around two high-impact platforms: LB-100, the first clinical-stage PP2A inhibitor, and the LiGHT Proton Therapy System, a next-generation radiotherapy technology. Together, these assets target some of the most persistent challenges in cancer treatment, including therapeutic resistance and limited access to precision radiation.
LB-100 continues to show promise as a treatment amplifier capable of enhancing chemotherapy, immunotherapy, and radiation across resistant tumor types. Its development is supported by collaborations with leading institutions and global pharmaceutical partners.
The acquisition of Liora Technologies’ LiGHT platform positions LIXTE to address the global shortfall in proton therapy access through a cost-efficient, highly precise, and scalable solution. This platform adds long-term commercial potential through an operational revenue model.
With validated technology, strong partnerships, and entry into rapidly growing oncology markets, LIXTE stands at an inflection point where scientific innovation and strategic expansion align, creating a compelling opportunity for investors monitoring the sector.
This communication is a sponsored advertisement. Pursuant to an agreement between 10XProTrader.com and OEJ ENT, 10XProTrader.com has received a sponsorship fee of twenty-five thousand USD to publicly disseminate information about LIXT.
We maintain zero positions in all profiled stocks and do not trade in any securities we feature. We do not, under any circumstances, accept stock as compensation for sponsored advertising.
Before accessing information obtained from 10XProTrader.com website and/or reading the report, including any sub- domains, affiliated websites, or through our other points of media (collectively the “Media”) which are owned and/or maintained by 10XProTrader.com (“we,” “our,” “us”), are governed by the policies, terms, and conditions set forth below. Please read our terms carefully. We offer 10XProTrader.com website/ the report, including any sub- domains thereof, affiliated websites, or our other points of media (collectively the “Media”) to you, the user/viewer, conditioned upon your acceptance of all terms, conditions, policies, and notices stated here. By viewing 10XProTrader.com website and/or reading the report, including any sub-domains thereof, affiliated websites, or our other points of media (collectively the “Media”) you agree to the terms set forth herein. If you do not agree to these terms and conditions in their entirety, you are not authorized to use the 10XProTrader.com website and/or the report, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) in any manner or form whatsoever.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our report, and email, or through our other points of media (collectively the “Media”) is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly, or indirectly constitutes a solicitation of the purchase or sale of any securities.
10XProTrader.com nor its principals are not FINRA-registered broker-dealers or investment advisers. The content of this report, email and or through our other points of media (collectively the “Media”) should not be taken as advice, an endorsement, or a recommendation from 10XProTrader.com to buy or sell any security. Always be extremely careful and consult a licensed investment professional before making any investment decision as investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
10XProTrader.com sponsored advertisements, and non-sponsored profiles do not purport to provide an analysis of any company’s financial position, operations, or prospects and this is not to be construed as a recommendation by 10XProTrader.com, or an offer or solicitation to buy or sell any security. Viewers should always consult with a licensed securities professional before making any type of investment decision. 10XProTrader.com does not provide trading, investment or tax advice, and readers shall not rely on statements by 10XProTrader.com employees which purport to provide such advice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk.
Through use of 10XProTrader.com website and/or reading the report, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) viewing or using you agree to hold 10XProTrader.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. 10XProTrader.com sponsored advertisements, and non-sponsored profiles do not purport to provide an analysis of any company’s financial position, operations, or prospects and this is not to be construed as a recommendation by 10XProTrader.com, or an offer or solicitation to buy or sell any security. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. 10XProTrader.com and its employees are not a Registered Investment Advisor, Broker Dealer, or a member of any association for other research providers in any jurisdiction whatsoever. 10XProTrader.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and 10XProTrader.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead 10XProTrader.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks.
The Publisher disclaims, expressly and implicitly, all warranties of any kind and as such, any use of the Advertisement is at the recipient’s own risk. The Publisher is not responsible or liable for any person’s reliance on or use of the Advertisement, including any success or failure that is directly or indirectly related to such person’s use of the Advertisement. The Publisher specifically cautions recipients of the Advertisement that the Advertisement should not be considered to be true or complete and as such, should not be relied upon for any purpose. The Publisher is not responsible for misleading or untrue statements or omissions in the Advertisements and is not responsible for actions taken by any person who relies upon the Advertisement. The Publisher is not nor is it qualified to act as: (i) an investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level, (ii) a broker-dealer or an individual acting in the capacity of a registered representative or broker-dealer, (iii) a stock picker, (iv) a securities trading or investment expert, (v) a securities researcher or analyst, (vi) a financial planner or one who engages in financial planning, a party who provides advice about buy, sell or hold recommendations as to specific securities; or (vii) a party or an agent offering securities for sale or soliciting their purchase. References in the Advertisements that refer to any security as a “stock pick” means it is a stock advertised by the Publisher and is not an indication the security has been picked, chosen, selected, researched, or recommended by the Publisher or that Publisher is qualified to select, research, or recommend stocks. All terms used in the Advertisement with respect to an Advertised Issuer and/or its securities including “profit”, “stock pick” or “target price”, are rhetorical statements and exaggerations and as such, should not be construed as truthful.
The Publisher makes no warranty or representation about the Advertisement. The Advertisement is not complete and should not be considered accurate or a source of information for the purposes of making an investment decision. The Publisher disclaims, expressly and implicitly, all warranties of any kind and as such, should a Recipient rely upon the Advertisement to make an investment decision (against the Publisher’s advice), it is a huge mistake and at his or her own risk. Recipients should not rely on the Advertisement for any purpose especially in connection with an investment decision. The Publisher is not responsible or liable for any person’s use of the Advertisement or any success or failure that is directly or indirectly related to such person’s use of the Advertisement for any purpose including trading securities of the Advertised Issuers. The Publisher is not responsible for omissions or errors in the Advertisement and the Publisher is not responsible for actions taken by any person who relies upon the Advertisement. The Publisher is not providing advice about purchasing, selling, or holding securities and is not offering securities for sale or soliciting their purchase. The Publisher is not and does not make stock recommendations and it is only a party publishing information. The Publisher does not act in the capacity of an adviser, consultant, stock picker, securities researcher, securities trading expert, securities analyst, investment adviser, broker-dealer, registered representative, and the Publisher is not qualified to act in any of the foregoing capacities. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SEC filings can be viewed at EDGAR: https://www.sec.gov/edgar/search/. 10XProTrader.com is compliant with the Can Spam Act of 2003. 10XProTrader.com does not offer such advice or analysis, and 10XProTrader.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
All direct and third-party compensation received will be disclosed within each individual email in accordance with section 17(b) of the 1933 Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. 10XProTrader.com has not investigated the background of the third party, the hiring company. Anyone viewing 10XProTrader.com website and/or reading the report, and advertisement, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) and advertisement should assume that the hiring party and affiliates of the hiring party own shares of the profiled company of which they will liquidate, further understanding that the liquidation of those shares will most likely impact the share price of the profiled company negatively. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm. Questions regarding any information contained in this 10XProTrader.com website and/or the report, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) may be sent to info@10XProTrader.com. Some of the content in this report may contain forward-looking information within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the profiled companies and the value of their securities.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned in our releases. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, 10XProTrader.com has relied upon information supplied by its customers, public information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed.
Investors should not rely on the information contained in 10XProTrader.com website and/or the report, or email, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”). 10XProTrader.com electronically disseminates information (the “Information”) on its website, in newsletters, featured reports, email or text list, spam compliant opt in email communications or otherwise pertaining to Profiled Companies’ (the “issuer” or “issuers” or “profiled company” or “profiled companies”), the securities of which are most frequently common stock shares quoted onthe (“NASDAQ”) Exchange, the (“NYSE American”) Exchange. Further specific financial information, filings, and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) and the Financial Industry Regulatory Authority (“FINRA”). Investors should use the information contained in this 10XProTrader.com website and/or the report, or email, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) as a starting point for doing additional independent research on the featured companies. The advertisements in this 10XProTrader.com website and/or the report, or email, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) are believed to be reliable, however, 10XProTrader.com and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and 10XProTrader.com has no obligation to update any of the information provided. 10XProTrader.com, its owners, officers, directors, contractors, and employees are not responsible for errors and omissions. From time-to-time certain content in our releases, website, or email is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro-cap market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our report or on our website may not have approved certain or any statements within the website or email. 10XProTrader.com encourages viewers to supplement the information obtained from 10XProTrader.com website and/or the report, or email, including our other points of media (collectively the “Media”) with independent research and other professional advice. 10XProTrader.com is not responsible for any claims made by the companies advertised herein, nor is 10XProTrader.com responsible for any other advertising agency, its program, or its structure. By accessing, viewing, or using the website or communications originating from this release, you agree that 10XProTrader.com, its owners, officers, directors, contractors, and employees, are not responsible for any content, associated links, resources, or services associated with a third-party website. You further agree that 10XProTrader.com, its owners, officers, directors, contractors, and employees shall not be liable for any loss or damage of any sort associated with your use of third-party content. Links and access to these sites are provided for your convenience only. 10XProTrader.com uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrongdoing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold 10XProTrader.com, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of 10XProTrader.com website and/or the report, or email, including any sub-domains, affiliated websites, or through our other points of media (collectively the “Media”) or the information in our press releases, profiles, and opinions. You agree that use of this 10XProTrader.com website and/or the report, email, including any sub-domains, affiliated websites, or our other points of media (collectively the “Media”) is at your sole risk. 10XProTrader.com disclaims all warranties of any kind, express or implied.
i - https://lioratechnologies.com/assets/docs/LIORA_LIXT_INV_Presentation_nov25th.pdf
ii - https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf
iii - https://d1io3yog0oux5.cloudfront.net/_c61ea0cac8a91a7d71e057f25bc5e9c6/lixte/db/1159/11014/pdf/Lixte+Corporate+Presentation+October+2025.pdf
iv - https://www.visionresearchreports.com/oncology-market/41161
v - https://finance.yahoo.com/news/lixte-biotechnology-acquires-liora-technologies-133000418.html
vi - https://www.biospace.com/press-releases/colorectal-cancer-drugs-market-size-projected-to-reach-us-19-96-billion-by-2033-says-datam-intelligence
vii - https://www.biospace.com/press-releases/ovarian-cancer-drugs-market-size-to-hit-usd-7-34-billion-by-2034
viii - https://www.marketresearchfuture.com/reports/soft-tissue-sarcoma-market-5304
ix - https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lixt/lixte-biotechnology-holdings/health